Vasa Therapeutics jobs and careers
As of October 24, 2026, Vasa Therapeutics has no open roles listed.
About Vasa Therapeutics
Vasa Therapeutics is a San Diego-based, private biotechnology company committed to the discovery and development of therapeutics that target pathophysiology of cardiovascular aging. Vasa Therapeutics has three active preclinical programs: 1. VS-041 is the first personalized medicine-based treatment of HFpEF. VS-041 shows robust reduction of cardiac fibrosis in a preclinical HFpEF model and inhibits release of signaling collagen fragments, such as PRO-C6, that mediate fibroinflammatory responses and are biomarkers of worse outcomes in HFpEF patients. Phase 1 clinical trial of VS-041 is planned for 2024. 2. Long acting apelin peptide analogs for combination treatment with incretins in obesity patients at risk for skeletal muscle loss or cardiovascular disease. As a monotherapy, long acting apelin agonists could also be beneficial in muscle atrophy, heart failure, chronic kidney disease, and peripheral artery disease. 3. A best-in-class inhibitor of CamKIId for heart failure and life-threatening arrhythmias.
Founded by Chris Larson.
- Employees
- 11 to 50
- Total funding
- $8.3M
Leadership
The top of Vasa Therapeutics's org chart, with how many people report into each leader.
Artur Plonowski
CEO and Co-Founder
Jobs at Vasa Therapeutics
No open positions right now. Explore more companies on TheJobsMap.
Vasa Therapeutics jobs: common questions
- Is Vasa Therapeutics hiring right now?
- Vasa Therapeutics has no open roles listed as of October 24, 2026. Roles appear here as soon as they are posted on Vasa Therapeutics's careers site.
- Who leads Vasa Therapeutics?
- Artur Plonowski, CEO and Co-Founder, is at the top of Vasa Therapeutics's org chart.
- How do I apply for a job at Vasa Therapeutics?
- Pick a role on Vasa Therapeutics's TheJobsMap page and select Apply. Every listing links to the original posting on Vasa Therapeutics's own careers site, so you apply directly with the employer.